🎗️ October is Breast Cancer Awareness Month 🎗️ In recognition of this, we will be releasing daily one-pagers this week, featuring educational literature on breast cancer. Stay tuned for updates! #breastcancerawareness #evidencebased #stayinformedwithInpharmD #MedTwitter

Exciting news! InpharmD is launching an AI Expert Series where pharmacy leaders will discuss AI's role in clinical and health system pharmacy. Stay tuned, more details to come! #stayinformedwithInpharmD #AIinPharmacy #druginformation #evidencebased #MedTwitter

For our next testimonial, we had the pleasure to chat with Dr. Isha Rana, Associate Director of Ambulatory Pharmacy at Mount Sinai Health System! We're thrilled that to help clinical teams drive evidence-based care! #stayinformedwithinpharmd #evidencebasedmedicine #MedTwitter

Have you heard our latest Evidence Based Medicine (EBM) podcast? Tune in as we discuss the SURMOUNT-OSA trials assessing tirzepatide for sleep apnea: Spotify: open.spotify.com/episode/105… Apple: podcasts.apple.com/us/podcas… #druginformation #evidencebasedmedicine #MedTwitter

Read InpharmD's clinical summaries on newly approved FDA medications for the month of July: AHZANTIVE® (aflibercept-mrbb) inpharmd.com/blogs/new-fda-a…… PYZCHIVA® (ustekinumab-ttwe) inpharmd.com/blogs/new-fda-a…… #MedTwitter #StayInformedWithInpharmD #DrugInformation #Evidencebased

KISUNLA™ (donanemab-azbt) inpharmd.com/blogs/new-fda-a… EPYSQLI™(eculizumab-aagh) inpharmd.com/blogs/new-fda-a… FEMLYV™ (ethinyl estradiol and norethindrone acetate) inpharmd.com/blogs/new-fda-a…

InpharmD Annual Retreat! A huge congrats to Atlanta Tech Village on their new office in Downtown! We had a blast seeing the new location!

We have four new FDA approval updates this week! Read the InpharmD summaries on our blog. 1. Capvaxive™ - inpharmd.com/blogs/new-fda-a… 2. Vigafyde™ - inpharmd.com/blogs/new-fda-a… 3. Yimmugo® - inpharmd.com/blogs/new-fda-a… 4. Sofdra™ - inpharmd.com/blogs/new-fda-a… #MedTwitter #StayInpharmD

Single-dose rasburicase with frequent laboratory monitoring is effective in the management of TLS and offers significant cost reductions. Read full response here: inpharmd.com/inquiries/15520 #MedTwitter #DrugInformation

The FDA recently approved mRESVIA, an mRNA RSV vaccine, to protect adults aged 60 years and older from lower respiratory tract disease. Read the InpharmD summary here: inpharmd.com/blogs/new-fda-a… #druginformation #evidencebasedmedicine #newdrugapproval #MedTwitter

Have you listened to our latest podcast? In this episode, we talk about excoriation (skin-picking) disorder and potential treatment options. Spotify – open.spotify.com/episode/0yd… Apple – podcasts.apple.com/us/podcas… #pharmacypodcast #druginformation #medtwitter #evidencebasedcare

The FDA recently approved BKEMV™, the first biosimilar referencing Soliris (eculizumab) for treating paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Read InpharmD's summary below: inpharmd.com/blogs/new-fda-a… #druginformation #MedTwitter

The FDA recently approved YESAFILI™(aflibercept-jbvf) and OPUVIZ™(aflibercept-yszy) as interchangeable biosimilars to Eylea (aflibercept). Read InpharmD's clinical summary here: inpharmd.com/blogs/new-fda-a… #druginformation #evidencebased #MedTwitter

In the adult population, lacosamide appears to be both safe and tolerable as an IV push at dosages up to 400 mg, with bradycardia not being a significant side effect. Read the full InpharmD inquiry here: inpharmd.com/inquiries/3b8d0… #druginfo #evidencebased #pharmacy #MedTwitter

The FDA recently approved IMDELLTRA™ (tarlatamab-dlle), a bispecific T-cell engager (BiTE) for the treatment of small cell lung cancer (SCLC) that has progressed on or after platinum-based chemotherapy. Read InpharmD's summary: inpharmd.com/blogs/new-fda-a… #MedTwitter #DrugInfo

MYHIBBIN™, an oral liquid formulation of mycophenolate mofetil, is indicated to prevent organ rejection in adults and children (3 months+) with kidney, heart, or liver transplants. Learn more here:inpharmd.com/blogs/new-fda-a… #druginformation #evidencebased #MedTwitter

Case reports indicate that symptoms of rash presented over 2 to 7 days after methylphenidate administration in majority of patients Read InpharmD's DI response here: inpharmd.com/inquiries/496d5… #druginformation #evidencebased #MedTwitter